Loading clinical trials...
Loading clinical trials...
A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Conditions
Interventions
VB11
Surgery
+2 more
Locations
4
United States
University of California, Los Angeles (UCLA)
Los Angeles, California, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
UT Health San Antonio MD Anderson Cancer Center (Mays Cancer Center)
San Antonio, Texas, United States
Huntsman Cancer Institute (HCI), University of Utah
Salt Lake City, Utah, United States
Start Date
August 1, 2020
Primary Completion Date
August 1, 2024
Completion Date
August 1, 2024
Last Updated
June 10, 2025
NCT05969860
NCT02800486
NCT05789394
NCT00083512
NCT05839379
NCT06860594
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions